PTIX

Protagenic Therapeutics, Inc.

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 4/10/2017
Contact Info
  • 149 Fifth Avenue
  • Suite 500
  • New York, NY 10010

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Deregistered a/o Mar 30, 2012
Audited Financials Audited
Latest Report Mar 31, 2017 10-Q
CIK 0001022899
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 7389 - Business services, misc
Incorporated In: DE, USA
Year of Inc. 1994
Employees 3 a/o Mar 31, 2017
Company Officers/Contacts
Alexander K. Arrow CFO
Carol Haggerty Administrator
Company Directors
Garo H. Armen Executive Chairman, Nominating Committee Member
Khalil Barrage Independent Director, Audit Committee Member, Compensation Committee Member
Gregory Ekizian Independent Director, Audit Committee Member, Compensation Committee Member
Josh Silverman Independent Director, Compensation Committee Member, Nominating Committee Member
Robert B. Stein Nominating Committee Member
Service Providers
Accounting/Auditing Firm
Marcum LLP
750 Third Ave
11th Floor
New York, NY, 10017
United States
 
MaloneBailey, LLP
9801 Westheimer Road
Suite 1100
Houston, TX, 77042
United States
 
Securities Counsel
Meister Seelig & Fein LLP
125 Park Avenue
7th Floor
New York, NY, 10017
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Atrinsic, Inc. until 7-2016
  • Formerly=New Motion, Inc. until 6-2009
  • Formerly=MPLC, Inc. until 5-07
  • Formerly=MPLC, Inc. (formerly Millbrook Press Inc. (The)) until 8-06
  • Note=12-5-05 final bankruptcy distribution made to eligible shareholders & company continues to trade as a shell
  • Note=10-20-05 company is a shell, intending to acquire assets or shares of an entitiy in a business that generates revenues
  • Note=2-6-04 company filed petition under Chapter XI of the Federal Bankruptcy Code in the U.S. Bankruptcy Court for the District of Connecticut
PTIX Security Details
Share Structure
Market Value1 $20,522,838 a/o Jun 21, 2017
Authorized Shares 100,000,000 a/o Dec 31, 2016
Outstanding Shares 10,261,419 a/o May 27, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Shareholders
Shareholders of Record 434 a/o Apr 18, 2017
Short Selling Data
Short Interest 11 (-8.33%)
May 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security